01480nas a2200193   4500000000100000008004100001260001500042653004300057653002900100653002700129100001600156700001600172700002000188700002100208245007200229856007200301520089900373022001401272       2026                            d  c2026-05-1410aautomation and high-throughput systems10acomplex disease modeling10aiPSC-derived organoids1 aXingrui Mou1 aNathan Dale1 aKiran Ramnarine1 aFilippo Cipriani00aAutomated stem cell-derived organoid platforms for disease modeling  uhttps://www.sciencedirect.com/science/article/pii/S01677799260014843 aComplex diseases arise from genetic, environmental, and lifestyle factors, the combination of which is difficult to model. Conventional animal and 2D cell culture models have limitations in scalability, reproducibility, or human relevance. Human-induced pluripotent stem cells (iPSCs) can be differentiated into 3D organoids that better mimic human biology. However, organoid protocols can be lengthy, variable, and labor-intensive, limiting high-throughput applications. Suspension bioreactors and multilineage differentiation have improved yield and function, but challenges remain in tissue maturity, vascularization, and consistency. Automated high-throughput liquid handling systems are emerging as a solution, enabling large-scale, reproducible production. Here, we discuss how combining iPSC-derived organoids with automation is poised to transform disease modeling and drug development.  a0167-7799